NN-9487
- Generic Name
- NN-9487
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
Phase 1
Recruiting
- Conditions
- OverweightObesity
- Interventions
- Drug: Placebo (NNC0487-0111)
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT06820476
- Locations
- 🇨🇳
Jinan Central Hospital, Ji'Nan, Shandong, China
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT06559527
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
Phase 2
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (NNC0487-0111)
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 125
- Registration Number
- NCT06064006
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸Novo Nordisk INvestigational Site, San Antonio, Texas, United States
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT06049329
- Locations
- 🇯🇵
Hakata Clinic, Fukuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath